Selecting the Right Frontline ADC for Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss how recent advances in frontline antibody-drug conjugate (ADC) therapy are enabling a more individualized approach to the management of metastatic triple-negative breast cancer (mTNBC). The faculty explains that selecting the most appropriate frontline ADC requires careful consideration of multiple patient- and disease-specific factors, including biomarker status, extent and pace of disease, performance status, comorbidities, and prior treatment history. They also highlight the importance of evaluating practical considerations such as work responsibilities, caregiving obligations, travel to the infusion center, and treatment schedules when selecting therapy. NP Zafman emphasizes that differences in toxicity profiles, including gastrointestinal and ocular adverse events, should be incorporated into shared decision-making to help identify the most appropriate treatment for each patient. Throughout the discussion, the speakers reinforce that successful frontline treatment selection requires balancing clinical evidence with patient preferences, quality-of-life goals, and individualized supportive care planning for patients with metastatic triple-negative breast cancer.